Compare AVAH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | EYPT |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2005 |
| Metric | AVAH | EYPT |
|---|---|---|
| Price | $6.58 | $13.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.75 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 987.6K | 792.6K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $2,433,199,000.00 | $7,539,000.00 |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $5.59 | $3,115.57 |
| P/E Ratio | $6.28 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.73 | $5.46 |
| 52 Week High | $10.32 | $19.11 |
| Indicator | AVAH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 50.65 |
| Support Level | $6.11 | $13.61 |
| Resistance Level | $6.93 | $14.54 |
| Average True Range (ATR) | 0.26 | 0.74 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 36.94 | 60.93 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.